有条件批准-话题@MedSci

#有条件批准#

9篇内容 | 897人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2027184, encodeId=b021202e18447, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=NMPA有条件批准安徽智飞龙科马生物重组新冠病毒蛋白疫苗, objectType=article, longId=299961, objectId=b68c29996149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b68c29996149, replyNumber=0, likeNumber=83, createdTime=2022-07-26, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b68c29996149, moduleTitle=NMPA有条件批准安徽智飞龙科马生物重组新冠病毒蛋白疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b68c29996149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027183, encodeId=5732202e183d6, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=FDA对渤健公司Aducanumab有条件批准，专家激辨！, objectType=article, longId=219190, objectId=1fa22191902e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fa22191902e, replyNumber=0, likeNumber=66, createdTime=2022-10-07, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fa22191902e, moduleTitle=FDA对渤健公司Aducanumab有条件批准，专家激辨！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fa22191902e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027181, encodeId=1865202e181a9, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=创新药“九期一”有条件批准上市！用于轻至中度阿尔茨海默病, objectType=article, longId=182295, objectId=1b7b1822954e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b7b1822954e, replyNumber=0, likeNumber=57, createdTime=2020-09-28, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b7b1822954e, moduleTitle=创新药“九期一”有条件批准上市！用于轻至中度阿尔茨海默病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b7b1822954e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027182, encodeId=54aa202e182b5, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=中国监管机构有条件批准绿谷药业甘露寡糖二酸治疗轻度至中度阿尔茨海默病, objectType=article, longId=182362, objectId=f1f4182362f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1f4182362f6, replyNumber=0, likeNumber=100, createdTime=2020-06-03, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1f4182362f6, moduleTitle=中国监管机构有条件批准绿谷药业甘露寡糖二酸治疗轻度至中度阿尔茨海默病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1f4182362f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027180, encodeId=b27d202e1809a, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=刚刚！CFDA公开征求临床急需药品有条件批准上市的技术指南意见, objectType=article, longId=124186, objectId=625912418676, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=625912418676, replyNumber=0, likeNumber=64, createdTime=2018-06-07, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=625912418676, moduleTitle=刚刚！CFDA公开征求临床急需药品有条件批准上市的技术指南意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=625912418676)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027179, encodeId=53ee202e179b5, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=国外罕见病药物入华提速：可有条件批准上市再补做研究, objectType=article, longId=98903, objectId=b700989031d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b700989031d, replyNumber=0, likeNumber=57, createdTime=2017-06-30, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b700989031d, moduleTitle=国外罕见病药物入华提速：可有条件批准上市再补做研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b700989031d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027178, encodeId=6b18202e17832, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=强生结核新药Situro获欧盟有条件批准, objectType=article, longId=31689, objectId=fbaa3168964, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbaa3168964, replyNumber=0, likeNumber=72, createdTime=2014-05-25, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbaa3168964, moduleTitle=强生结核新药Situro获欧盟有条件批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbaa3168964)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027177, encodeId=796a202e17712, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=CHMP建议有条件批准强生结核病药物Sirturo, objectType=article, longId=28634, objectId=bee9286347e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee9286347e, replyNumber=0, likeNumber=67, createdTime=2014-05-30, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee9286347e, moduleTitle=CHMP建议有条件批准强生结核病药物Sirturo, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee9286347e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027176, encodeId=4130202e17621, content=<a href='/topic/show?id=f138606661a' target=_blank style='color:#2F92EE;'>#有条件批准#</a>, objectTitle=罗氏基底细胞癌药物Erivedge获欧盟有条件批准, objectType=article, longId=21569, objectId=0673215694b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0673215694b, replyNumber=0, likeNumber=54, createdTime=2013-11-17, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0673215694b, moduleTitle=罗氏基底细胞癌药物Erivedge获欧盟有条件批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0673215694b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

有条件批准

2020-05-29

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

NMPA有条件批准安徽智飞龙科马生物重组新冠病毒蛋白疫苗

2022-07-26

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

FDA对渤健公司Aducanumab有条件批准，专家激辨！

2022-10-07

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

创新药“九期一”有条件批准上市！用于轻至中度阿尔茨海默病

2020-09-28

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

中国监管机构有条件批准绿谷药业甘露寡糖二酸治疗轻度至中度阿尔茨海默病

2020-06-03

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

刚刚！CFDA公开征求临床急需药品有条件批准上市的技术指南意见

2018-06-07

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

国外罕见病药物入华提速：可有条件批准上市再补做研究

2017-06-30

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

强生结核新药Situro获欧盟有条件批准

2014-05-25

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

CHMP建议有条件批准强生结核病药物Sirturo

2014-05-30

yangjxjc (审核中...)

前往app查看评论内容

#有条件批准#

罗氏基底细胞癌药物Erivedge获欧盟有条件批准

2013-11-17

科室
- - 订阅+
  - 更多科室
工具
服务